Asthma Clinical Trial
Official title:
Body Plethysmograph Measurements Before and After Methacholine Challenge in Early Childhood
In our previous study of Methacholine Challenge Tests (MCT) in preschool children, we found
that wheeze detection was associated with significant reduction in flows and vital capacity
values. We hypothesized that this finding is associated with trapped-air rather than the
children's loss of cooperation/concentration.
Objectives: To test this hypothesis by attempting plethysmography measurements during MCT.
In young children that cannot perform adequately spirometry methacholine challenge test
(MCT) is continued until any of the following clinical signals occurred: appearance of
audible wheeze, a fall of >5% in O2-saturation, or an increase of >50% in respiratory rate
and/or heart rate. In our previous study [1] we assessed the feasibility of determining
PC20-FEV1 in relation to audible wheeze detection during MCT in asthmatic preschool
children. We found that at end of test (EOT), the reduction in flows of the forced
expiratory flow volume (FEFV) curves was accompanied by reduction in forced vital capacity
(FVC) though reductions in flows were higher than the reduction in volume. We hypothesized
that this finding is associated with trapped-air rather than the children's loss of
cooperation or concentration. We have also thought that determining lung volume by whole
body plethysmograpy, has the advantage of measuring airway resistance in relation to FRC.
Hence, plethysmographic measurements of lung volumes during MCT may shed light on the
physiological relation between airway obstruction and hyperinflation at the end of MCT when
audible wheeze is detected. However, plethysmography requires the patient's cooperation and
coordination to perform brief panting maneuvers against closed airways. So far, only airway
resistance has been measured in the plethysmograph [10], as it is believed that young
children will not comply with the occlusions needed for lung volume measurements within the
plethysmograph.
The aims of the present study were twofold: a) to test if young children are capable of
performing plethysmographic maneuvers required for FRC measurements; and b) to investigate
if the reduction in vital capacity at maximal reduction in flows of the FEFV curves, found
at wheeze detection during MCT, is due to true elevation of FRC and air trapping, or is
artificially related to patients’ loss of motivation/cooperation.
Methods:
Lung volumes and airway resistance will be measured in a commercial, whole body ZAN500
constant volume body plethysmograph (ZAN-Messgeraete GmbH, Germany). The plethysmograph is
equipped with a graphic display for preschool children to increase cooperation. The chair
can be adjusted so that the child can comfortably sit up straight with a nose-clip, and
reach the mouthpiece without flexing the neck.
The plethysmography procedure will be performed according to recommendations. The test
events will be explained to the child in detail outside of the plethysmograph. After that,
the measurements will be carried out in the same sequence that was explained to the child.
FRC will be measured by allowing for 2-3 breathing attempt series of superimposed straight
lines (separated only by thermal drift). The best test out of two technically accepted
series was analyzed.
MCT will be performed according to the ATS guidelines for the Methacholine Challenge Test.
Tests will be performed in a designated room at the Pediatric Pulmonary Unit, Meyer
Children’s Hospital, Haifa, Israel. A parent and the investigating team will be present
throughout the test. Tests will be performed with triple doses of fresh Methacholine
solutions (0.057 to13.395 mg/ml) dissolved in saline. Solutions will be driven by a KoKo-PDS
dosimeter (Ferraris Respiratory, Louisville, CO) via mouthpiece while the child was sitting
upright with a nose-clip and breathing at least 10 deep breaths. Five-minute intervals will
be taken between concentrations until the maximal concentration or the end point will be
reached (see below). Oxygen saturation and heart-rate will be monitored continuously by
pulse-oximetry (Ohmeda Biox 3700 Pulse Oximeter, USA). Auscultation for 20-seconds over the
trachea and two zones of both lungs (upper front and lower back) will be performed according
to recommendation. The following indices will be considered as EOT: appearance of audible
wheeze, a fall of 5% in O2-saturation, or an increase of 50% in respiratory rate and/or
heart rate. Nebulized Albuterol (2.5mg) was administrated after lung function measurements.
Spirometry: FEFV curves will be measured with a KoKo PDS commercial spirometer (Ferraris
Respiratory, Louisville, CO), using the program incentives targets (peak expiratory flow
rates or vital capacity). Calibration was performed before the testing sessions. The curves
will be monitored on the computer screen to ensure best effort. On-line rejection of curves
will be based on published quality control for older and preschool children including visual
inspection for "non-cooperation" errors, which included poor effort, incomplete expiration,
cough and glottis closure. Acceptable curves had to show a rapid rise to peak flow, and a
gradual, smooth decline of flow down to residual volume.
Sequence of lung function tests: Baseline measurements included spirometry followed by
plethysmography. After baseline measurements MCT will be performed. A duplicate spirometry
set will be performed immediately after auscultation and during the interval between
inhalations. Plethysmography will be repeated following the last spirometry at EOT and after
auscultation.
;
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|